news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

According to the Zhitong Finance APP, Luye Pharma (02186) issued an announcement that the group's independently developed Class 1 innovative drug LY03020 has been approved by the Drug Review Center of the China National Drug Administration to conduct clinical trials and is intended to be used to treat schizophrenia and Alzheimer's psychotic disorder (ADP).

LY03020 is developed based on the Group's new molecular entity/new therapeutic entity technology platform (NCE/NTE). It is the world's first dual-target agonist of trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 2C receptor (5-HT2CR), and is a new generation of antipsychotic drug.

Preclinical studies have shown that LY03020 can significantly improve the positive and negative symptoms and cognitive impairment of schizophrenia, and can significantly improve the positive and negative symptoms of ADP, without obvious extrapyramidal reactions (EPS) and metabolic syndrome risks such as weight gain and abnormal glucose and lipid metabolism. It is expected to better meet clinical needs.